Literature DB >> 25740109

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".

Sung-Hyun Kim1, Dong-Wook Kim2.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; radotinib

Mesh：

Substances：

Year:  2015        PMID： 25740109      PMCID： PMC4349295          DOI： 10.3324/haematol.2014.123232

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

2.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Authors:  Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

Review 3.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.

Authors:  Dong-Wook Kim; Yeow-Tee Goh; Hui-Hua Hsiao; Priscilla B Caguioa; Dongho Kim; Wan-Seok Kim; Tapan Saikia; Shruti Agrawal; Amit Roy; David Dai; M Brigid Bradley-Garelik; Jaydip Mukhopadhyay; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2009-05-20       Impact factor: 2.490

4.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Authors:  A Hochhaus; M Baccarani; M Deininger; J F Apperley; J H Lipton; S L Goldberg; S Corm; N P Shah; F Cervantes; R T Silver; D Niederwieser; R M Stone; H Dombret; R A Larson; L Roy; T Hughes; M C Müller; R Ezzeddine; A M Countouriotis; H M Kantarjian
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

5.  Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Authors:  Sung-Hyun Kim; Hari Menon; Saengsuree Jootar; Tapan Saikia; Jae-Yong Kwak; Sang-Kyun Sohn; Joon Seong Park; Seong Hyun Jeong; Hyeoung Joon Kim; Yeo-Kyeoung Kim; Suk Joong Oh; Hawk Kim; Dae Young Zang; Joo Seop Chung; Ho Jin Shin; Young Rok Do; Jeong-A Kim; Dae-Young Kim; Chul Won Choi; Sahee Park; Hye Lin Park; Gong Yeal Lee; Dae Jin Cho; Jae Soo Shin; Dong-Wook Kim
Journal:  Haematologica       Date:  2014-04-04       Impact factor: 9.941

6.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

7.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Authors:  Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

8.  Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Charles T Chuah; Hirohisa Nakamae; Zhixiang X Shen; M Brigid Bradley-Garelik; Dong-Wook Kim
Journal:  Leuk Lymphoma       Date:  2014-03-12
  8 in total
  1 in total

Review 1.  Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Authors:  Ahmet Emre Eskazan; Dilek Keskin
Journal:  Ther Adv Hematol       Date:  2017-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.